NCT04123379 2026-05-20Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)Icahn School of Medicine at Mount SinaiPhase 2 Completed48 enrolled